| ¿µ¹® | toxicity | ÇÑ±Û | µ¶¼º |
|---|---|---|---|
| ¼³¸í | »ýü¿¡ ÀÖ¾î ¹Ù¶÷Á÷ÇÏÁö ¾ÊÀº ¾à¹° ÀÛ¿ëÀ» ¸»ÇÑ´Ù. ¾à¹°À» °ú·®À¸·Î »ç¿ëÇϸé Áßµ¶À» ÀÏÀ¸Å°¸ç, ½ÉÇÑ °æ¿ì¿¡´Â Á×À½¿¡ À̸£´Âµ¥ ÀÌ´Â ¾à¹°ÀÇ ±Þ¼º µ¶¼ºÀÌ´Ù. ¸¸¼º µ¶¼ºÀº ¼Ò·®À» Àå±â°£ ¹Ýº¹ ¼·ÃëÇÏ¿´À» ¶§ÀÇ µ¶¼ºÀÌ´Ù. °£, ÄáÆÏ µî ¿©·¯ Àå±â¿Í Á¶Á÷¿¡ ´ëÇÑ µ¶¼º ¿Ü¿¡, ±âÇüÀ¯¹ß¼º, ¹ß¾Ï¼º µîµµ ¾à¹°µ¶¼ºÀÌ´Ù. ¾à¹°µ¶¼ºÀÇ °¾àÀº ±Þ¼º µ¶¼º°Ë»ç(LD50), ¸¸¼º µ¶¼º°Ë»ç, ±âÇüÀ¯¹ß°Ë»ç, ¹ß¾Ï°Ë»ç, ¹ø½Ä°Ë»ç ±âŸ ¿©·¯ µ¿¹°°Ë»ç¿¡ ÀÇÇØ ÆÇÁ¤µÈ´Ù. |
||
| ¿µ¹® | VDRL(venereal disease research laboratory) | ÇÑ±Û | ¼ºº´ ¿¬±¸½ÇÇè½Ç |
|---|---|---|---|
| ¼³¸í | ¸Åµ¶±ÕÀÇ reagin¿¡ ´ëÇÑ Ç×ü. ¸Åµ¶ÀÇ ¼±º°°Ë»ç·Î »ç¿ëµÇ¸ç ¸Åµ¶ Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ ¿©ºÎ¿Í Ä¡·áÈ¿°ú ÆÇÁ¤¿¡µµ »ç¿ëµÈ´Ù. ¸Åµ¶¿Ü¿¡µµ Àü½Å¼ºÈ«¹Ý¼º³¶Ã¢, ·ù¸¶Æ¼½º°üÀý¿° µî¿¡¼µµ ¾ç¼ºÀ¸·Î ³ªÅ¸³¯ ¼ö ÀÖ´Ù. |
||
| ¿µ¹® | Dilatation and Curettage(D & C) | ÇÑ±Û | Àڱñܾ¼ú, ÀڱøñÈ®Àå |
|---|---|---|---|
| ¼³¸í | ÀÚ±ÃÀ̶õ žư¡ ¼öÅÂµÇ¾î¼ ºÐ¸¸Àü±îÁö ¹ßÀ°ÇÏ°í ¼ºÀåÇÏ´Â °ø°£ÀÌ´Ù. Àڱüӿ¡ º´º¯ÀÌ ÀÖ¾î ÀÓ½ÅÀÌ °è¼ÓµÉ ¼ö ¾ø°Å³ª ¾Æ´Ï¸é ´Ù¸¥ ÀÌÀ¯·Î ÀӽŵǾî Àִ žƸ¦ Á¦°ÅÇϰíÀÚ ÇÒ °æ¿ì¿¡ »ç¿ëµÇ´Â ¹æ¹ýÀÌ´Ù. ¿©±â¼ ±Ü¾î³»±â À§ÇÏ¿©´Â ¿ì¼± ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇÏ´Â ÀڱøñÀ» È®Àå½ÃÄÑ¾ß ÇÑ´Ù. ¿©±â¿¡´Â ±Þ¼ÓÈ÷ È®ÀåÀ» ½ÃµµÇÏ´Â ¹ý°ú ¼¼È÷ È®ÀåÀ» ½ÃµµÇÏ´Â 2°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ÀڱøñÀ» ±Þ¼ÓÈ÷ È®ÀåÇÒ ¶§´Â Çì°¡¸£ ¸ñ°üÈ®Àå±â(Hegar's dilatator)¸¦ »ç¿ëÇÑ´Ù. À̰ÍÀº ÀÛÀº ±Ý¼Ó¸·´ë·Î ÀÛÀº Å©±âºÎÅÍ Å« Å©±â±îÁö ´Ù¾çÇÑ Å©±â°¡ ÀÖ¾î¼ ¿ì¼± ÀÛÀº ¸·´ë·Î ½ÃÀÛÇÏ¿© Á¡Á¡ Å« Å©±âÀÇ ¸·´ë¸¦ Àڱøñ¿¡ ³Ö¾î¼ ÀڱøñÀ» È®Àå½ÃŲ´Ù. ¼¼È÷ È®Àå½Ãų ¶§´Â Laminaria tent¸¦ ¸ñ°ü¿¡ »ðÀÔÇÏ´Â ¹æ¹ýÀ» »ç¿ëÇÑ´Ù. Laminaria tent¶õ ÇØÃÊ·Î ¸¸µç ÀÛÀº ¸·´ë·Î ¼öºÐÀ» Èí¼öÇϸé Á¡Á¡ ´Ã¾î³ª´Â ¼ºÁúÀÌ ÀÖ´Ù. À̰ÍÀ» ÀÚ±ÃÀÇ ¸ñ¿¡ ³ÖÀ¸¸é À̰ÍÀÌ ¼öºÐÀ» Èí¼öÇÏ¿© ´Ã¾î³ª¹Ç·Î õõÈ÷ ÀÚ±ÃÀÇ ¸ñÀÌ ´Ã¾î³´Ù. ÀڱøñÀÌ ÃæºÐÈ÷ ´Ã¾î³ª¸é ±× ¼ÓÀ¸·Î ³¡ÀÌ ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ ³Ö¾î¼ ÀڱüÓÀÇ º´º¯À̳ª ÀÓ½ÅµÈ Å¾Ƹ¦ ±Ü¾î³»´Âµ¥ ¿©±â¿¡ »ç¿ëµÇ´Â ¼ù°¡¶ôó·³ »ý±ä ±â±¸¸¦ Å¥·¿À̶ó°í ÇÑ´Ù. Ãʱâ ÀÓ½ÅÁßÀý Áï À¯»ê°ú °°Àº ÀӽŰú °ü·ÃµÈ °æ¿ì»Ó¸¸ ¾Æ´Ï¶ó, ºñÀӽŠÀÚ±ÃÀÇ Àڱ󻸷Á¶Á÷ÀÇ Ã¤Ãë ¹× Á¦°Å¸¦ À§Çؼµµ ÇàÇØÁö´Â ¼ö±âÀÌ´Ù. ÀÌ´Â ¿øÄ¢ÀûÀ¸·Î ¸¶ÃëÇÏ¿¡ ½Ç½ÃµÇ´Â °ÍÀ¸·Î Àڱøñ°üÀ» È®ÀåÇÏ°í ±â±¸·Î Àڱà ³»¿ë¹°À» Á¦°ÅÇϰí Å¥·¿À¸·Î Àڱ󻺮À» ±ú²ýÀÌ ÇÑ´Ù. ÀÚ±Ãõ°øÀ̳ª ÀڱøñÀÇ ÆÄ¿ µîÀÇ À§ÇèÀÌ µû¸£¸ç, ¼ö¼úÈÄ °¨¿° ¶Ç´Â ÃâÇ÷ µî¿¡ ´ëÇÑ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù. |
||
| ¿µ¹® | eye | ÇÑ±Û | ´«, ¾È±¸ |
|---|---|---|---|
| ¼³¸í | ´«È® ¾È¿¡ ¹ÚÇôÀÖ´Â °ø¸ð¾çÀÇ ½Ã°¢±â°üÀÌ´Ù. ¾È±¸´Â 3ÃþÀÇ ÇǸ·(°ø¸·)°ú °¢¸·, ¸Æ¶ô¸·, ¸Á¸·¿¡ ½Î¿© ÀÖ´Ù. °¢°¢ÀÇ ÇǸ·Àº ¸î °³ÀÇ ÃþÀ¸·Î ³ª´©¾îÁø´Ù. 3ÃþÀÇ ÇǸ· Áß¿¡´Â ºûÀ» ±¼ÀýÇÏ´Â ¸Åü[¹æ¼ö, ¼öÁ¤Ã¼, À¯¸®Ã¼¾×]ÀÌ ÀÖ´Ù. ¿ÜÃøÀÇ °ø¸·Àº ¹é»öÀÌ¸ç ¼¶À¯»ó Á¶Á÷ÀÌ´Ù. °ø¸·ºÎ¿¡¼´Â ½Ã°¢½Å°æ¼¶À¯°¡ äÆÇÀÇ ÀÛÀº±¸¸ÛÀ» ÅëÇØ¼ ¾È±¸³»·Î µé¾î°£´Ù. °ø¸·ÀÇ ³»Ãø Ç¥¸éÀº ¼¶¼¼ÇÑ °áÇÕÁ¶Á÷°ú °¥»öÆÇ¿¡ ÀÇÇØ¼ ¸Æ¶ô¸·°ú Á¢Çϰí ÀÖ´Ù. °¢¸·Àº 5ÃþÀ̸ç, ±× ³»ÃþÀº À帷À¸·Î¼ µ¥½º¸Þ¸·À̶ó ºÒ¸®°í ÀÖ´Ù. Æ÷µµ¸·Àº ÁÖ·Î Ç÷°ü°ú »ö¼Ò·Î µÇ¾î ÀÖ´Ù. ¾ÕºÎ´Â ¼öÁ¤Ã¼ÀÇ ÁÖº¯ºÎ·Î¼ ¼¶¸ðüµ¹±â¶ó ºÒ¸®´Â ÁÖ¸§ÀÇ ÇüÀ¸·Î ³¡³´Ù. ¸Á¸·Àº ÁÖ·Î ½Å°æÁ¶Á÷À¸·Î¼ Å©°Ô´Â ¼¼°³ÀÇ ÃþÀ¸·Î µÇ¾î ÀÖ´Ù. ¿ÜÃþ¸·Àº ½Å°æ¼¼Æ÷·Î µÇ¾î ÀÖ°í ±× Çü»ó¿¡ µû¶ó ¿ø»Ôü¿Í ¸·´ëü·Î ºÒ¸°´Ù. ȫä´Â Áß¾Ó¿¡ µ¿°øÀ» °®´Â ºÎºÐÀ¸·Î, À±»ó°ú ¹æ»ç»óÀÇ ÆòȰ±Ù¼¶À¯¸¦ °®°í ÀÖ´Ù. ȫäÀÇ »öÀº ¿©·¯ °¡ÁöÀ̸ç, ¼öÁ¤Ã¼ÀÇ ¾Õ ¹æ¼öÁß¿¡ À§Ä¡Çϰí ÀÖ´Ù. ¼¶¸ðüÀδë´Â ȫ並 µÑ·¯½Î°í ÀÖ´Â °í¸®¸ð¾çÀÇ °áÇÕ¼¶À¯ÀÌ´Ù. ¼¶À¯Ã¼±ÙÀº ȫäÀÇ ÁÖÀ§¸¦ µÑ·¯½Î°í, Á¶ÀýÇÒ ¶§´Â ¼öÁ¤Ã¼ÀÇ ÇüÀ» ¹Ù²Û´Ù. ¹æ¼ö´Â ÀüºÎÀÇ °¢¸·°ú ÈĺÎÀÇ ¼öÁ¤Ã¼ »çÀÌ¿¡ ÀÖ´Ù. À¯¸®Ã¼¾×Àº ¼öÁ¤Ã¼ ÈĺÎÀÇ °ø°£À» ä¿ì¸ç, Åõ¸íÇÑ Á©¸®»óÀÇ ¹°ÁúÀ̰í, À¯¸®Ã¼¸·¿¡ ½Î¿© ÀÖ´Ù. ¼öÁ¤Ã¼´Â À¯¸®Ã¼¾×°ú ¹æ¼öÀÇ »çÀÌ¿¡ ÀÖ´Â ¾çÂÊÀÌ º¼·ÏÇÑ Åõ¸íÇÑ ¹°Ã¼·Î, ź¼ºÇǸ·°ú ¼Ò´ëÀδ뿡 ÀÇÇØ¼ ¾Ë¸ÂÀº Àå¼Ò¿¡ ´Þ·Á ÀÖ´Ù. ´«ÀÇ µ¿¸ÆÀº ªÀº ¼¶¸ðüµ¿¸Æ, ±ä¼¶¸ðüµ¿¸Æ, Àü¼¶¸ðüµ¿¸Æ, ¸Á¸·Á߽ɵ¿¸Æ µîÀÌ´Ù. ½Å°æÀº ½Ã°¢½Å°æ, ±ä¼¶¸ðü½Å°æ, ªÀº ¼¶¸ðü ½Å°æµîÀÌ´Ù. |
||
| ECG | Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ = EKG 1. Conducting System Structu... |
|---|---|
| ERF | Education and Research Foundation; external rotation in flexion; Eye Research Foundation |
| I&T | intolerance and toxicity |
| EUROTOX | European Committee on Chronic Toxicity Hazards |
| TCLP | Toxicity Characteristic Leachate Procedure [EPA battery test] |
| CTC | Common Toxicity Criteria |
|---|---|
| DLT | Dose limiting toxicity |
| RRT | Regimen related toxicity |
| TCLP | Toxicity Characteristic Leaching Procedure |
| TIE | Toxicity Identification Evaluation |
| united states agency for health care policy and research | An agency of the public health service established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery.." it supersedes the national centre for health services research. (12 Dec 1998) |
|---|---|
| substance of lens of eye | That which constitutes the lens of the eye, composed of a nucleus and a cortex and covered by an epithelium. Synonym: substantia lentis. (05 Mar 2000) |
| eye lens | <physics> The lens nearest the eye in any ocular. (05 Aug 1998) |
| lens, eye | <microscopy> The lens in an eyepiece nearest to the eye. (05 Aug 1998) |
| acute toxicity | <pharmacology> Illness resulting from a single dose or exposure to a toxic substance. Compare: chronic toxicity. (06 May 1997) |
| chronic toxicity | <pharmacology> Illness caused by repeated or long-term exposure to low doses of a toxic substance. Compare: acute toxicity. (09 Oct 1997) |
| digitalis toxicity | A result of the over-accumulation of digitalis glycosides in the body. Kidney insufficiency can be a contributing factor. Symptoms include nausea, vomiting, visual changes, blurred vision, anorexia and palpitations. Treatment is emergent as life-threatening cardiac arrhythmias are possible with higher blood levels. (27 Sep 1997) |
| digoxin toxicity | A result of the over-accumulation of digitalis glycosides in the body. Kidney insufficiency can be a contributing factor. Symptoms include nausea, vomiting, visual changes, blurred vision, anorexia and palpitations. Treatment is emergent as life-threatening cardiac arrhythmias are possible with higher blood levels. (27 Sep 1997) |
| drug toxicity | The systemic effects of a drug that are related to the overall level of the medication in the bloodstream. Drug toxicity may occur with overdosage of a medication, accumulation of the drug in the body over time or the inability of the patients body to eliminate the drug. (27 Sep 1997) |
| oxygen toxicity | A body disturbance resulting from breathing high partial pressures of oxygen; characterised by visual and hearing abnormalities, unusual fatigue while breathing, muscular twitching, anxiety, confusion, incoordination, and convulsions; although the mechanism for development of the condition is obscure, a disruption of enzymatic activity is likely, perhaps as a result of free radical formation. Synonym: oxygen poisoning. (05 Mar 2000) |
| toxicity | The quality of being poisonous, especially the degree of virulence of a toxic microbe or of a poison. (18 Nov 1997) |
| toxicity test | <investigation> Controlled laboratory test to determine the toxicity of a chemical to an organism in terms of specific chemical concentrations. An acute toxicity test establishes the concentration required to kill a predetermined proportion of test organisms within a relatively short period of time, typically 4 days or less. A chronic toxicity test reveals the effects of a sublethal concentration applied throughout all or part of the life cycle. (12 Jan 1998) |
| toxicity tests | Tests that determine the toxicity of a substance. These include tests of clinical drugs, foods, environmental pollutants, etc. (12 Dec 1998) |
| ep toxicity | A test defined by the federal Environmental Protection Agency to check a substance for the presence of arsenic, barium, cadmium, chromium, lead, mercury, selenium, or silver. 40 CFR 261.24 defines the concentrations constituting hazardous waste and the test procedure. (05 Dec 1998) |
| Venereal Disease Research Laboratory | <microbiology> A blood test used to diagnose syphilis. Read as nonreactive or negative if you do not have syphilis. The Venereal Disease Research Laboratory can also be positive is cases of leprosy, malaria, mononucleosis, lupus, hepatitis A and pregnancy. Positive Venereal Disease Research Laboratory tests are usually followed up by a more specific test (FTA antibodies). (12 Jan 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|